What is IGC stock price today?

IGC (Igc Pharma Inc) stock is trading at $0.31 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IGC stock going up or down today?

IGC stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IGC stock now?

The decision to buy IGC depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IGC a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IGC based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IGC stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IGC is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IGC's P/E ratio?

P/E ratio data for IGC will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IGC's market cap?

IGC (Igc Pharma Inc) has a market capitalization of $0.03 billion, making it a small-cap stock.

What is IGC's price to book ratio?

IGC trades at a price-to-book (P/B) ratio of 3.95, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IGC pay dividends?

IGC does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IGC's dividend yield?

IGC does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IGC stock a good long-term investment?

IGC's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IGC's revenue growth rate?

IGC has shown revenue growth of -0.5% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for IGC are available on our dashboard with complete income statement analysis.

What are the risks of investing in IGC?

Key risks for IGC include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IGC compare to its competitors?

Compare IGC to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IGC's performance and positioning.

What is IGC's stock price target for 2026?

Our AI model provides price targets for IGC based on fundamental analysis: Bull case $0.40 (+30%), Base case $0.36 (+15%), Bear case $0.28 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IGC?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IGC. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IGC's next earnings report?

IGC reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IGC - Igc Pharma Inc

NYSE * Health Care * Biotechnology

$0.31

+$0.01 (+4.41%)

About Igc Pharma Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Key Statistics

Market Cap

$30.64M

P/B Ratio

3.95

EPS

$-0.06

Revenue Growth

-0.5%

Employees

How IGC Compares to Peers

IGC is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IGC(This stock)	$30.64M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.26B	20.4	-0%	0.1%	vs BIIB

Igc Pharma Inc Company Information

Headquarters: Maryland; U.S.A
Website: igcpharma.com
Sector: Health Care
Industry: Biotechnology

IGC - Igc Pharma Inc

About Igc Pharma Inc

IGC Key Statistics

How IGC Compares to Peers

Igc Pharma Inc Company Information

IGC Lician Score

IGC Financial Snowflake

Upcoming Events for IGC